Monotherapy of experimental metabolic syndrome: I. Efficacy and safety

American Diabetes Association (2002). Management of dyslipidemia in adults with diabetes. Diabetes Care25: 74–77.Search in Google Scholar

Balcerczyk A, Bartosz G, Drzewinska J, Piotrowski Ł, Pulaski Ł, Stefek M. (2014). Antioxidant action of SMe1EC2, the low-basicity derivative of the pyridoindole stobadine, in cell free chemical models and at cellular level. Interdiscip Toxicol7: 27–32.Search in Google Scholar

Davidson M. (2008). Review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome. Am J Cardiol102:19L–27L.10.1016/j.amjcard.2008.09.071Open DOISearch in Google Scholar

De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. (2003). European guidelines on cardiovascular disease prevention in clinical practice: Third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil10: S1–10.Search in Google Scholar

Drimal J, Knezl V, Navarova J, Nedelcevova J, Paulovicova E, Sotnikova R, Snirc V, Drimal D. (2008). Role of inflammatory cytokines and chemoattractants in the rat model of streptozotocin-induced diabetic heart failure. Endocr Regul42: 129–135.Search in Google Scholar

Gáspárová Z, Snirc V, Stolc S. (2011). The new pyridoindole antioxidant SMe1EC2 and its intervention in hypoxia/hypoglycemia-induced impairment of longterm potentiation in rat hippocampus. Interdiscip Toxicol4: 56–61.Search in Google Scholar

Isomaa B. (2003). A major health hazard: the metabolic syndrome. Life Sci73: 2395–2411.Search in Google Scholar

Kabaklić A, Fras Z. (2017). Moderate-dose atorvastatin improves arterial endothelial function in patients with angina pectoris and normal coronary angiogram: a pilot study. Arch Med Sci13: 827–836.10.5114/aoms.2017.68238Open DOISearch in Google Scholar

Klimes I, Vrána A, Kunes J, Seböková E, Dobesová Z, Stolba P, Zicha J. (1995). Hereditary hypertriglyceridemic rat: a new animal model of metabolic alterations in hypertension. Blood Press4: 137–142.Search in Google Scholar

Knezl V, Sotníková R, Brnoliaková Z, Bauer V, Bezek Š. (2017). Monotherapy of experimental metabolic syndrome II. Study of cardiovascular effects. Interdiscip Toxicol10(2):Search in Google Scholar

Kwasny C, Manuwald U, Kugler J, Horm U. (2017). Systematic review of the epidemiology and natural history of the metabolic vascular syndrome and its coincidence with Type 2 diabetes mellitus and cardiovascular diseases in different european countries. Metab Res. doi: 10.1055/s-0043-122395. [Epub ahead of print]PMID:29183091) ].10.1055/s-0043-122395Search in Google Scholar

Liao JK. (2002). Beyond lipid lowering: The role of statins in vascular protection. Int J Cardiol86: 5–18.10.1016/S0167-5273(02)00195-XOpen DOISearch in Google Scholar

Mendrick DL, Diehl AM, Topor LS, Dietert RR, Will Y, La Merrill MA, Bouret S, Varma V, Hastings KL, Schug TT, Emeigh Hart SG, Burleson FG. (2017). Metabolic syndrome and associated diseases: From the bench to the clinic. Toxicol Sci doi: 10.1093/toxsci/kfx233. [Epub ahead of print].10.1093/toxsci/kfx233Search in Google Scholar

Meerarani P, Badimon JJ, Zias E, Fuster V, Moreno PR. (2006). Metabolic syndrome and diabetic atherothrombosis: implications in vascular complications. Curr Mol Med6: 501–514.10.2174/156652406778018680Open DOISearch in Google Scholar

Mézešová L, Jendruchová-Javorková V, Vlkovičová J, Kyselova Z, Navarová J, Bezek S, Vrbjar N. (2012). Antioxidant SMe1EC2 may attenuate the disbalance of sodium homeostasis in the organism induced by higher intake of cholesterol. Mol Cell Biochem 366: 41–48.Search in Google Scholar

Paravicini TM and Touyz RM. (2006). Redox signaling in hypertension. Cardiovasc Res 71: 247–258.Search in Google Scholar

Pekiner B, Ulusu, NN, Das-Evcimen N, Sahilli M, Aktan F, Stefek M, Stolc S, Karasu I. (2002). In vivo treatment with stobadine prevents lipid peroxidation, protein glycation and calcium overload but does not ameliorate Ca2+-ATPase activity in heart and liver of streptozotocin-diabetic rats: comparison with vitamin E. Biochim Biophys Acta1588: 71–78.10.1016/S0925-4439(02)00141-2Open DOISearch in Google Scholar

Raal FJ. (2009). Pathogenesis and management of the dyslipidemia of the metabolic syndrome. Metab Syndr Relat Disord7: 83–88.Search in Google Scholar

Rai KN, Kumari NS, Gowda Km D, Kr S (2013). The evaluation of micronutrients and oxidative stress and their relationship with the lipid profile in healthy adults. J Clin Diagn Res.7: 1314–1318.Search in Google Scholar

Stefek M, Sotnikova R, Okruhlicova L, Volkovova K, Kucharska J. (2000). Effect of dietary supplementation with the pyridoindole antioxidant stobadine on antioxidant state and ultrastructure of diabetic rat myocardium. Acta Diabetol37: 111–117.Search in Google Scholar

Štolc S, Šnirc V, Májeková M, Gáspárová Z, A. Gajdošíková A, Štvrtina S. (2006). Development of the new group of indole-derived neuroprotective drugs affecting oxidative stress. Cell Mol Neurobiol26: 1493–1502.10.1007/s10571-006-9037-916705480Open DOISearch in Google Scholar

Ujhazy E, Dubovicky M, Ponechalova V, Navarova J, Brucknerova I, Snirc V, Mach M. (2008). Prenatal developmental toxicity study of the pyridoindole antioxidant SMe1EC2 in rats. Neuro Endocrinol Lett29: 639–643.Search in Google Scholar

Ujhazy E, Mach M, Navarova J, Brucknerova I, Dubovicky M. (2011). Safety assessment of the pyridoindole derivative SMe1EC2: developmental neurotoxicity study in rats. Interdiscip Toxicol4: 47–51.Search in Google Scholar

Vakhrushev YM, Lyapina MV (2017). Enteral failure and metabolic syndrome: Common neurohormonal mechanisms of development, possibilities of their rational therapy. Ter Arkh.89: 95–101.Search in Google Scholar

Wihastuti TA and Heriansyah T. (2017). The inhibitory effects of polysaccharide peptides (PsP) of Ganoderma lucidum against atherosclerosis in rats with dyslipidemia. Heart Int 12: e1–e7.10.5301/heartint.5000234546069329114382Open DOISearch in Google Scholar

Yamada Y, Takeuchi S, Yoneda M, Ito S, Sano Y, Nagasawa K, Matsuura N, Uchinaka A, Murohara T, Nagata K. (2017). Atorvastatin reduces cardiac and adipose tissue inflammation in rats with metabolic syndrome. Int J Cardiol240: 332–338.Search in Google Scholar

Zamani E, Mohammadbagheri M, Fallah M, Shaki F. (2017). Atorvastatin attenuates ethanol-induced hepatotoxicity via antioxidant and anti-inflammatory mechanisms. Res Pharm Sci12: 315–321.10.4103/1735-5362.212049556600628855943Open DOISearch in Google Scholar

Zicha J, Pechanova O, Cacanyiova S, Cebova M, Kristek F, Torok J, Simko F, Dobesova Z, Kunes J. (2006). Hereditary hypertriglyceridemic rat: a suitable model of cardiovascular disease and metabolic syndrome? Physiol Res55: S49–S63.10.33549/physiolres.930000.55.S1.49Search in Google Scholar